It turns out, from the data on Table 1, that CD133 (prominin-1) has been established as a marker of CSC on many solid tumors including brain, colon, liver, lung, ovarian, pancreatic, and prostate tumors. This evidence concerns the gene PROM1 and prostate neoplasm.